{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:18:27Z","timestamp":1770747507896,"version":"3.49.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,2,27]],"date-time":"2010-02-27T00:00:00Z","timestamp":1267228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s11886-010-0083-z","type":"journal-article","created":{"date-parts":[[2010,2,26]],"date-time":"2010-02-26T06:21:05Z","timestamp":1267165265000},"page":"99-107","source":"Crossref","is-referenced-by-count":26,"title":["The Pathogenesis of Aortopathy in Marfan Syndrome and Related Diseases"],"prefix":"10.1007","volume":"12","author":[{"given":"Jeffrey A.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"Ikonomidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,27]]},"reference":[{"key":"83_CR1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ajmg.c.30068","volume":"139","author":"HC Dietz","year":"2005","unstructured":"Dietz HC, Loeys B, Carta L, Ramirez F: Recent progress towards a molecular understanding of Marfan syndrome. Am J Med Genet C Semin Med Genet 2005, 139:4\u20139.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"83_CR2","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0140-6736(05)67789-6","volume":"366","author":"DP Judge","year":"2005","unstructured":"Judge DP, Dietz HC: Marfan\u2019s syndrome. Lancet 2005, 366:1965\u20131976.","journal-title":"Lancet"},{"key":"83_CR3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.0.CO;2-R","volume":"62","author":"A Paepe De","year":"1996","unstructured":"De Paepe A, Devereux RB, Dietz HC et al.: Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996, 62:417\u2013426.","journal-title":"Am J Med Genet"},{"key":"83_CR4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cpcardiol.2007.10.001","volume":"33","author":"NM Ammash","year":"2008","unstructured":"Ammash NM, Sundt TM, Connolly HM: Marfan syndrome-diagnosis and management. Curr Probl Cardiol 2008, 33:7\u201339.","journal-title":"Curr Probl Cardiol"},{"key":"83_CR5","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/sj.ejhg.5201851","volume":"15","author":"JC Dean","year":"2007","unstructured":"Dean JC: Marfan syndrome: clinical diagnosis and management. Eur J Hum Genet 2007, 15:724\u2013733.","journal-title":"Eur J Hum Genet"},{"key":"83_CR6","first-page":"684","volume":"79","author":"IH Maumenee","year":"1981","unstructured":"Maumenee IH: The eye in the Marfan syndrome. Trans Am Ophthalmol Soc 1981, 79:684\u2013733.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"83_CR7","first-page":"726","volume":"43","author":"RE Pyeritz","year":"1988","unstructured":"Pyeritz RE, Fishman EK, Bernhardt BA, Siegelman SS: Dural ectasia is a common feature of the Marfan syndrome. Am J Hum Genet 1988, 43:726\u2013732.","journal-title":"Am J Hum Genet"},{"key":"83_CR8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1161\/01.CIR.11.3.321","volume":"11","author":"VA McKusick","year":"1955","unstructured":"McKusick VA: The cardiovascular aspects of Marfan\u2019s syndrome: a heritable disorder of connective tissue. Circulation 1955, 11:321\u2013342.","journal-title":"Circulation"},{"key":"83_CR9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0002-9149(83)90138-8","volume":"52","author":"HE Sisk","year":"1983","unstructured":"Sisk HE, Zahka KG, Pyeritz RE: The Marfan syndrome in early childhood: analysis of 15 patients diagnosed at less than 4\u00a0years of age. Am J Cardiol 1983, 52:353\u2013358.","journal-title":"Am J Cardiol"},{"key":"83_CR10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/adc.84.2.129","volume":"84","author":"CD Karnebeek van","year":"2001","unstructured":"van Karnebeek CD, Naeff MS, Mulder BJ, et al.: Natural history of cardiovascular manifestations in Marfan syndrome. Arch Dis Child 2001, 84:129\u2013137.","journal-title":"Arch Dis Child"},{"key":"83_CR11","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.1093\/emboj\/16.22.6659","volume":"16","author":"X Yuan","year":"1997","unstructured":"Yuan X, Downing AK, Knott V, Handford PA: Solution structure of the transforming growth factor beta-binding protein-like module, a domain associated with matrix fibrils. EMBO J 1997, 16:6659\u20136666.","journal-title":"EMBO J"},{"key":"83_CR12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1357-2725(98)00109-5","volume":"31","author":"F Ramirez","year":"1999","unstructured":"Ramirez F, Pereira L: The fibrillins. Int J Biochem Cell Biol 1999, 31:255\u2013259.","journal-title":"Int J Biochem Cell Biol"},{"key":"83_CR13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1152\/physiolgenomics.00092.2004","volume":"19","author":"F Ramirez","year":"2004","unstructured":"Ramirez F, Sakai LY, Dietz HC, Rifkin DB: Fibrillin microfibrils: multipurpose extracellular networks in organismal physiology. Physiol Genomics 2004, 19:151\u2013154.","journal-title":"Physiol Genomics"},{"key":"83_CR14","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1073\/pnas.96.7.3819","volume":"96","author":"L Pereira","year":"1999","unstructured":"Pereira L, Lee SY, Gayraud B, et al.: Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proc Natl Acad Sci U S A 1999, 96:3819\u20133823.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 2","key":"83_CR15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1242\/jcs.00229","volume":"116","author":"JP Annes","year":"2003","unstructured":"Annes JP, Munger JS, Rifkin DB: Making sense of latent TGFbeta activation. J Cell Sci 2003, 116(Pt 2):217\u2013224.","journal-title":"J Cell Sci"},{"key":"83_CR16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1083\/jcb.200608167","volume":"176","author":"SS Chaudhry","year":"2007","unstructured":"Chaudhry SS, Cain SA, Morgan A, et al.: Fibrillin-1 regulates the bioavailability of TGFbeta1. J Cell Biol 2007, 176:355\u2013367.","journal-title":"J Cell Biol"},{"key":"83_CR17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/bdrc.20000","volume":"72","author":"NL Charbonneau","year":"2004","unstructured":"Charbonneau NL, Ono RN, Corson GM, et al.: Fine tuning of growth factor signals depends on fibrillin microfibril networks. Birth Defects Res C Embryo Today 2004, 72:37\u201350.","journal-title":"Birth Defects Res C Embryo Today"},{"key":"83_CR18","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1074\/jbc.M209256200","volume":"278","author":"Z Isogai","year":"2003","unstructured":"Isogai Z, Ono RN, Ushiro S, et al.: Latent transforming growth factor betabinding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 2003, 278:2750\u20132757.","journal-title":"J Biol Chem"},{"key":"83_CR19","doi-asserted-by":"crossref","unstructured":"Dietz HC, Pyeritz RE: Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Hum Mol Genet 1995, 4 Spec No:1799\u20131809.","DOI":"10.1093\/hmg\/4.suppl_1.1799"},{"key":"83_CR20","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng1116","volume":"33","author":"ER Neptune","year":"2003","unstructured":"Neptune ER, Frischmeyer PA, Arking DE, et al.: Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003, 33:407\u2013411.","journal-title":"Nat Genet"},{"key":"83_CR21","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1172\/JCI200422715","volume":"114","author":"CM Ng","year":"2004","unstructured":"Ng CM, Cheng A, Myers LA, et al.: TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 2004, 114:1586\u20131592.","journal-title":"J Clin Invest"},{"key":"83_CR22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1124287","volume":"312","author":"JP Habashi","year":"2006","unstructured":"Habashi JP, Judge DP, Holm TM, et al.: Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006, 312:117\u2013121.","journal-title":"Science"},{"key":"83_CR23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1083\/jcb.200606058","volume":"175","author":"G Ge","year":"2006","unstructured":"Ge G, Greenspan DS: BMP1 controls TGFbeta1 activation via cleavage of latent TGFbeta-binding protein. J Cell Biol 2006, 175:111\u2013120.","journal-title":"J Cell Biol"},{"key":"83_CR24","doi-asserted-by":"crossref","unstructured":"\u2022 Tatti O, Vehvilainen P, Lehti K, Keski-Oja J: MT1-MMP releases latent TGF-beta1 from endothelial cell extracellular matrix via proteolytic processing of LTBP-1. Exp Cell Res 2008, 314:2501\u20132514. This is a study identifying elevated matrix metalloproteinase activity as a mediator of TGF-\u03b2 release from the LLC.","DOI":"10.1016\/j.yexcr.2008.05.018"},{"key":"83_CR25","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1146\/annurev.cellbio.21.022404.142018","volume":"21","author":"XH Feng","year":"2005","unstructured":"Feng XH, Derynck R: Specificity and versatility in TGF-beta signaling through Smads. Annu Rev Cell Dev Biol 2005, 21:659\u2013693.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"83_CR26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/35043051","volume":"1","author":"J Massague","year":"2000","unstructured":"Massague J: How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000, 1:169\u2013178.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"83_CR27","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.cardiores.2007.02.008","volume":"74","author":"M Ruiz-Ortega","year":"2007","unstructured":"Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, et al.: TGF-beta signaling in vascular fibrosis. Cardiovasc Res 2007, 74:196\u2013206.","journal-title":"Cardiovasc Res"},{"key":"83_CR28","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","volume":"113","author":"Y Shi","year":"2003","unstructured":"Shi Y, Massague J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113:685\u2013700.","journal-title":"Cell"},{"issue":"Pt 16","key":"83_CR29","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1242\/jcs.02554","volume":"118","author":"A Moustakas","year":"2005","unstructured":"Moustakas A, Heldin CH: Non-Smad TGF-beta signals. J Cell Sci 2005, 118(Pt 16):3573\u20133584.","journal-title":"J Cell Sci"},{"key":"83_CR30","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Carta L, Smaldone S, Zilberberg L, et al.: p38 MAPK is an early determinant of promiscuous Smad2\/3 signaling in the aortas of fibrillin-1 (Fbn1)-null mice. J Biol Chem 2009, 284:5630\u20135636. This is an informative paper describing noncanonical TGF-\u03b2 signaling in fibrillin-1-null mice. The authors demonstrated p38 MAPK can phosphorylate Smad2 independent of TGF-\u03b2 receptor kinase activity.","DOI":"10.1074\/jbc.M806962200"},{"key":"83_CR31","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/ncb1780","volume":"10","author":"A Sorrentino","year":"2008","unstructured":"Sorrentino A, Thakur N, Grimsby S, et al.: The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol 2008, 10:1199\u20131207.","journal-title":"Nat Cell Biol"},{"key":"83_CR32","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.molcel.2008.09.002","volume":"31","author":"M Yamashita","year":"2008","unstructured":"Yamashita M, Fatyol K, Jin C, et al.: TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell 2008, 31:918\u2013924.","journal-title":"Mol Cell"},{"key":"83_CR33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/ng1511","volume":"37","author":"BL Loeys","year":"2005","unstructured":"Loeys BL, Chen J, Neptune ER, et al.: A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005, 37:275\u2013281.","journal-title":"Nat Genet"},{"key":"83_CR34","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1056\/NEJMoa055695","volume":"355","author":"BL Loeys","year":"2006","unstructured":"Loeys BL, Schwarze U, Holm T, et al.: Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med 2006, 355:788\u2013798.","journal-title":"N Engl J Med"},{"key":"83_CR35","first-page":"123","volume":"129","author":"BL Halpern","year":"1971","unstructured":"Halpern BL, Char F, Murdoch JL, et al.: A prospectus on the prevention of aortic rupture in the Marfan syndrome with data on survivorship without treatment. Johns Hopkins Med J 1971, 129:123\u2013129.","journal-title":"Johns Hopkins Med J"},{"key":"83_CR36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1146\/annurev.med.59.103106.103801","volume":"59","author":"DP Judge","year":"2008","unstructured":"Judge DP, Dietz HC: Therapy of Marfan syndrome. Annu Rev Med 2008, 59:43\u201359.","journal-title":"Annu Rev Med"},{"key":"83_CR37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijcard.2005.11.116","volume":"114","author":"DR Gersony","year":"2007","unstructured":"Gersony DR, McClaughlin MA, Jin Z, Gersony WM: The effect of beta-blocker therapy on clinical outcome in patients with Marfan\u2019s syndrome: a meta-analysis. Int J Cardiol 2007, 114:303\u2013308.","journal-title":"Int J Cardiol"},{"key":"83_CR38","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJM199405123301902","volume":"330","author":"J Shores","year":"1994","unstructured":"Shores J, Berger KR, Murphy EA, Pyeritz RE: Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan\u2019s syndrome. N Engl J Med 1994, 330:1335\u20131341.","journal-title":"N Engl J Med"},{"key":"83_CR39","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.amjcard.2005.01.032","volume":"95","author":"AT Yetman","year":"2005","unstructured":"Yetman AT, Bornemeier RA, McCrindle BW: Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol 2005, 95:1125\u20131127.","journal-title":"Am J Cardiol"},{"key":"83_CR40","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.bjp.0704331","volume":"134","author":"A Daugherty","year":"2001","unstructured":"Daugherty A, Manning MW, Cassis LA: Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 2001, 134:865\u2013870.","journal-title":"Br J Pharmacol"},{"key":"83_CR41","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0895-7061(00)00298-3","volume":"13","author":"A Kubo","year":"2000","unstructured":"Kubo A, Fukuda N, Teng J, et al.: Angiotensin II regulates the cell cycle of vascular smooth muscle cells from SHR. Am J Hypertens 2000, 13:1117\u20131124.","journal-title":"Am J Hypertens"},{"key":"83_CR42","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1161\/01.CIR.0000165133.84978.E2","volume":"111","author":"J Rodriguez-Vita","year":"2005","unstructured":"Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, et al.: Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 2005, 111:2509\u20132517.","journal-title":"Circulation"},{"key":"83_CR43","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Brooke BS, Habashi JP, Judge DP, et al.: Angiotensin II blockade and aortic-root dilation in Marfan\u2019s syndrome. N Engl J Med 2008, 358:2787\u20132795. This is the initial clinical study demonstrating attenuation of aortic root dilation in patients with MFS treated with losartan.","DOI":"10.1056\/NEJMoa0706585"},{"key":"83_CR44","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Lacro RV, Dietz HC, Wruck LM, et al.: Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J 2007, 154:624\u2013631. This paper describes the multicenter randomized clinical trial comparing losartan and atenolol treatment in patients with MFS.","DOI":"10.1016\/j.ahj.2007.06.024"},{"key":"83_CR45","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1016\/S0021-9258(17)35666-1","volume":"261","author":"RA Ignotz","year":"1986","unstructured":"Ignotz RA, Massague J: Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986, 261:4337\u20134345.","journal-title":"J Biol Chem"},{"key":"83_CR46","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1006\/mgme.2000.3059","volume":"71","author":"EE Moussad","year":"2000","unstructured":"Moussad EE, Brigstock DR: Connective tissue growth factor: what\u2019s in a name? Mol Genet Metab 2000, 71:276\u2013292.","journal-title":"Mol Genet Metab"},{"key":"83_CR47","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1165\/ajrcmb.26.2.4666","volume":"26","author":"U Kucich","year":"2002","unstructured":"Kucich U, Rosenbloom JC, Abrams WR, Rosenbloom J: Transforming growth factor-beta stabilizes elastin mRNA by a pathway requiring active Smads, protein kinase C-delta, and p38. Am J Respir Cell Mol Biol 2002, 26:183\u2013188.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"83_CR48","first-page":"3111","volume":"263","author":"J Keski-Oja","year":"1988","unstructured":"Keski-Oja J, Raghow R, Sawdey M, et al.: Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem 1988, 263:3111\u20133115.","journal-title":"Divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem"},{"key":"83_CR49","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1541-7786.MCR-05-0140","volume":"4","author":"HJ Kwak","year":"2006","unstructured":"Kwak HJ, Park MJ, Cho H, et al.: Transforming growth factor-beta1 induces tissue inhibitor of metalloproteinase-1 expression via activation of extracellular signal-regulated kinase and Sp1 in human fibrosarcoma cells. Mol Cancer Res 2006, 4:209\u2013220.","journal-title":"Mol Cancer Res"},{"key":"83_CR50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jcp.20948","volume":"211","author":"C Yan","year":"2007","unstructured":"Yan C, Boyd DD: Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007, 211:19\u201326.","journal-title":"J Cell Physiol"},{"key":"83_CR51","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0014-4827(86)90038-8","volume":"164","author":"M Laiho","year":"1986","unstructured":"Laiho M, Saksela O, Keski-Oja J: Transforming growth factor beta alters plasminogen activator activity in human skin fibroblasts. Exp Cell Res 1986, 164:399\u2013407.","journal-title":"Exp Cell Res"},{"key":"83_CR52","first-page":"1375","volume":"25","author":"ES Kim","year":"2004","unstructured":"Kim ES, Kim MS, Moon A: TGF-beta-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells. Int J Oncol 2004, 25:1375\u20131382.","journal-title":"Int J Oncol"},{"key":"83_CR53","doi-asserted-by":"crossref","first-page":"19327","DOI":"10.1074\/jbc.M314048200","volume":"279","author":"N Selvamurugan","year":"2004","unstructured":"Selvamurugan N, Kwok S, Alliston T, et al.: Transforming growth factor-beta 1 regulation of collagenase-3 expression in osteoblastic cells by cross-talk between the Smad and MAPK signaling pathways and their components, Smad2 and Runx2. J Biol Chem 2004, 279:19327\u201319334.","journal-title":"J Biol Chem"},{"key":"83_CR54","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/jcp.21869","volume":"221","author":"GM Gordon","year":"2009","unstructured":"Gordon GM, Ledee DR, Feuer WJ, Fini ME: Cytokines and signaling pathways regulating matrix metalloproteinase-9 (MMP-9) expression in corneal epithelial cells. J Cell Physiol 2009, 221:402\u2013411.","journal-title":"J Cell Physiol"},{"key":"83_CR55","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.regpep.2009.04.012","volume":"155","author":"L Konrad","year":"2009","unstructured":"Konrad L, Scheiber JA, Schwarz L, et al.: TGF-beta1 and TGF-beta2 strongly enhance the secretion of plasminogen activator inhibitor-1 and matrix metalloproteinase-9 of the human prostate cancer cell line PC-3. Regul Pept 2009, 155:28\u201332.","journal-title":"Regul Pept"},{"key":"83_CR56","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1038\/sj.onc.1210046","volume":"26","author":"A Safina","year":"2007","unstructured":"Safina A, Vandette E, Bakin AV: ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells. Oncogene 2007, 26:2407\u20132422.","journal-title":"Oncogene"},{"key":"83_CR57","doi-asserted-by":"crossref","unstructured":"Blaney Davidson EN, Remst DF, Vitters EL, et al.: Increase in ALK1\/ALK5 ratio as a cause for elevated MMP-13 expression in osteoarthritis in humans and mice. J Immunol 2009, 182:7937\u20137945.","DOI":"10.4049\/jimmunol.0803991"},{"key":"83_CR58","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000103205","volume":"74","author":"V Cottin","year":"2007","unstructured":"Cottin V, Dupuis-Girod S, Lesca G, Cordier JF: Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (rendu-osler disease). Respiration 2007, 74:361\u2013378.","journal-title":"Respiration"},{"key":"83_CR59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10038-006-0078-1","volume":"52","author":"T Mizuguchi","year":"2007","unstructured":"Mizuguchi T, Matsumoto N: Recent progress in genetics of Marfan syndrome and Marfan-associated disorders. J Hum Genet 2007, 52:1\u201312.","journal-title":"J Hum Genet"},{"key":"83_CR60","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ajmg.c.30069","volume":"139","author":"H Pannu","year":"2005","unstructured":"Pannu H, Tran-Fadulu V, Milewicz DM: Genetic basis of thoracic aortic aneurysms and aortic dissections. Am J Med Genet C Semin Med Genet 2005, 139:10\u201316.","journal-title":"Am J Med Genet C Semin Med Genet"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-010-0083-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-010-0083-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-010-0083-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T00:01:42Z","timestamp":1635033702000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-010-0083-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,27]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["83"],"URL":"https:\/\/doi.org\/10.1007\/s11886-010-0083-z","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,27]]}}}